ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 106 filers reported holding ASCENDIS PHARMA A/S in Q4 2018. The put-call ratio across all filers is 0.16 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,568 | -99.7% | 29,218 | +123.0% | 0.01% | +150.0% |
| Q2 2022 | $1,218,000 | +413.9% | 13,105 | +548.8% | 0.00% | – |
| Q1 2022 | $237,000 | -39.8% | 2,020 | -42.3% | 0.00% | -100.0% |
| Q1 2020 | $394,000 | -70.2% | 3,500 | -74.5% | 0.00% | -66.7% |
| Q3 2019 | $1,320,000 | -18.3% | 13,700 | -46.9% | 0.00% | -25.0% |
| Q4 2018 | $1,616,000 | +12.2% | 25,799 | +27.0% | 0.00% | +33.3% |
| Q3 2018 | $1,440,000 | -25.2% | 20,315 | -29.8% | 0.00% | -40.0% |
| Q2 2018 | $1,926,000 | – | 28,952 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |